Loading
A phase 1/2 trial of YL201, Toripalimab, Cisplatin in nasopharyngeal carcinoma, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. is a phase 1/2 interventional study registered as NCT07258979 by MediLink Therapeutics (Suzhou) Co., Ltd., with 202 participants planned, started 2025-11-05 and due to reach its primary completion in 2028-02. Interventions recorded: YL201, Toripalimab, Cisplatin. Conditions listed: Recurrent or Metastatic Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares YL201, MediLink Therapeutics, Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma.
Shares Toripalimab, Platinum agents, Cisplatin, Cytotoxic chemotherapy.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics, Immune checkpoint inhibitors.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics.
Shares Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA), Nasopharyngeal carcinoma, Cisplatin, Cytotoxic chemotherapy.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Cisplatin, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/